A newly approved drug called sotagliflozin is giving fresh hope to people living with type 2 diabetes and kidney disease. These conditions are very common and often occur together, especially in older adults.
They also greatly increase the risk of serious heart problems such as heart attacks and strokes. Managing blood sugar alone is not enough for many patients, because their heart and blood vessels are also under constant strain.
This is why doctors are always looking for treatments that can protect more than just blood sugar levels.
Sotagliflozin is a new type of medicine that may offer this wider protection. It has recently been approved by the U.S. Food and Drug Administration, also known as the FDA. This approval came after strong evidence showed that the drug can lower the risk of dangerous heart events in people who are already at high risk.
To understand why this drug is different, it helps to know how the body handles sugar. When we eat food, sugar enters the bloodstream and is then processed by the body.
The kidneys play an important role in this process by filtering the blood and controlling how much sugar is kept or removed. Special proteins in the body help move sugar in and out of cells. Two of these proteins are called SGLT1 and SGLT2.
Most similar drugs only block SGLT2, which is mainly found in the kidneys. By blocking this protein, the body removes more sugar through urine, which helps lower blood sugar levels. However, sotagliflozin works in a broader way.
It blocks both SGLT1 and SGLT2. SGLT1 is found not only in the kidneys but also in the gut, heart, and even the brain. Because of this, the drug may have stronger and wider effects on the body.
A large international study tested how well this drug works. The study was led by Dr. Deepak L. Bhatt from Mount Sinai and involved over 10,500 patients. All participants had type 2 diabetes and chronic kidney disease, and many also had other risk factors for heart disease.
These patients were carefully divided into two groups. One group took sotagliflozin, while the other group took a placebo, which is a pill with no active medicine. The researchers followed the patients for about 16 months to see what happened over time.
The results were very encouraging. Patients who took sotagliflozin had a 23 percent lower risk of heart attacks, strokes, or death caused by heart disease compared to those who took the placebo.
This is a significant reduction, especially for people who already face a high risk of these events. It shows that the drug does more than control blood sugar. It also helps protect the heart and blood vessels.
This study, known as the SCORED trial, was published in The Lancet Diabetes & Endocrinology, a respected medical journal. It is the first study to clearly show that blocking both SGLT1 and SGLT2 can provide extra protection for the heart.
This makes sotagliflozin different from other drugs in the same group, which have not shown such strong effects on preventing heart attacks and strokes.
Doctors are especially interested in this finding because many patients with diabetes and kidney disease are at very high risk of heart problems. Even with current treatments, these risks remain high. Having a drug that can reduce this risk gives doctors a valuable new option.
Sotagliflozin has already been shown to reduce hospital visits for heart failure and lower the chance of death from heart disease. These new results add another important benefit by showing that it can also prevent heart attacks and strokes. This means it could play a larger role in future treatment plans.
Even so, researchers say more studies are needed to understand the long-term effects of this drug. Scientists want to know how it works over many years and whether it can help even more groups of patients. As more data becomes available, doctors will be better able to decide who will benefit most from this treatment.
For now, the findings bring hope to millions of people living with diabetes and kidney disease. A single drug that can manage blood sugar while also protecting the heart could make a big difference in daily life and long-term health. It also shows how medical research continues to move forward, offering better and safer ways to treat complex conditions.
If you care about stroke, please read studies about how to eat to prevent stroke, and diets high in flavonoids could help reduce stroke risk.
For more health information, please see recent studies about how Mediterranean diet could protect your brain health, and wild blueberries can benefit your heart and brain.
Copyright © 2026 Knowridge Science Report. All rights reserved.
